Korro Bio, Inc. (KRRO)
Total Valuation
Korro Bio has a market cap or net worth of $374.13 million. The enterprise value is $237.63 million.
Market Cap | 374.13M |
Enterprise Value | 237.63M |
Important Dates
The next estimated earnings date is Tuesday, April 9, 2024, before market open.
Earnings Date | Apr 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 8.02 million shares outstanding. The number of shares has increased by 499.32% in one year.
Shares Outstanding | 8.02M |
Shares Change (YoY) | +499.32% |
Shares Change (QoQ) | +107.10% |
Owned by Insiders (%) | 7.66% |
Owned by Institutions (%) | 72.04% |
Float | 2.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.20 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.87, with a Debt / Equity ratio of 0.20.
Current Ratio | 8.87 |
Quick Ratio | n/a |
Debt / Equity | 0.20 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -106.30% and return on invested capital (ROIC) is -41.62%.
Return on Equity (ROE) | -106.30% |
Return on Assets (ROA) | -72.30% |
Return on Capital (ROIC) | -41.62% |
Revenue Per Employee | n/a |
Profits Per Employee | -$854,442 |
Employee Count | 95 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $27,000 in taxes.
Income Tax | 27,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (1Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 55.99 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 79.87 |
Average Volume (30 Days) | 24,155 |
Short Selling Information
The latest short interest is 129,610, so 1.62% of the outstanding shares have been sold short.
Short Interest | 129,610 |
Short Previous Month | 123,995 |
Short % of Shares Out | 1.62% |
Short % of Float | 5.73% |
Short Ratio (days to cover) | 1.82 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -84.53M |
Pretax Income | -81.15M |
Net Income | -81.17M |
EBITDA | -73.91M |
EBIT | -81.15M |
Earnings Per Share (EPS) | -$53.08 |
Balance Sheet
The company has $169.71 million in cash and $33.21 million in debt, giving a net cash position of $136.51 million or $17.02 per share.
Cash & Cash Equivalents | 169.71M |
Total Debt | 33.21M |
Net Cash | 136.51M |
Net Cash Per Share | $17.02 |
Equity / Book Value | 169.91M |
Book Value Per Share | 21.18 |
Working Capital | 153.25M |
Cash Flow
In the last 12 months, operating cash flow was -$67.28 million and capital expenditures -$7.84 million, giving a free cash flow of -$75.12 million.
Operating Cash Flow | -67.28M |
Capital Expenditures | -7.84M |
Free Cash Flow | -75.12M |
FCF Per Share | -$49.12 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -499.32% |
Shareholder Yield | -499.32% |
Earnings Yield | -21.70% |
FCF Yield | -20.08% |
Analyst Forecast
The average price target for Korro Bio is $126.25, which is 41.02% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $126.25 |
Price Target Difference | 41.02% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 6, 2023. It was a reverse split with a ratio of 1:50.
Last Split Date | Nov 6, 2023 |
Split Type | Reverse |
Split Ratio | 1:50 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |